How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries.

Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks.

What if you'd invested in Veracyte (VCYT Quick QuoteVCYT - Free Report) ten years ago? It may not have been easy to hold on to VCYT for all that time, but if you did, how much would your investment be worth today?

Veracyte's Business In-Depth

With that in mind, let's take a look at Veracyte's main business drivers.

Headquartered in South San Francisco, CA, Veracyte, Inc. is a global diagnostics company that provides clinicians with valuable insights to diagnose and treat cancer. The company offers advanced genomic tests that leverage scientific, clinical and machine learning expertise. Presently, the portfolio includes Afirma (for thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer) and Decipher Bladder (bladder cancer), with additional tests in development. The company also has operations in San Diego, California, Austin, Texas and Haifa, Israel.

These tests improve diagnostic, prognostic, predictive and treatment decisions, helping patients avoid unnecessary procedures and reduce the time needed to find appropriate treatment options. In the United States, Veracyte offers its tests through central laboratories while making them accessible worldwide through collaborations with local labs. Outside the United States, the company provides its Prosigna test to laboratories and hospitals that can perform the test locally as an in vitro diagnostic (IVD) assay. Veracyte also plans to offer Prosigna as a laboratory-developed test (LDT) in 2026.

The company recognizes revenues from three sources:

Testing revenues (96% of total revenues in 2025, up 3.2% from 2024): Upon delivery of the test results, the company bills for testing services considering factors such as payer reimbursement history, contracts and coverage.

Product revenues (3% of 2025 revenues; flat): Includes revenues from Prosigna breast cancer assay, the nCounter Analysis System (acquired from Nanostring Technologies, Inc. in 2019) and related diagnostic kits.

Biopharmaceutical and other revenues (1% of 2025 revenues; down 200%): Includes revenues from licensing or providing access to the company’s assets and services, including testing and contract manufacturing.

The company’s 2021 acquisition of Decipher Biosciences expanded its genomic testing menu into urologic cancers and provided Decipher GRID (Genomic Resource for Intelligent Discovery) — a platform and database that helps drive biopharmaceutical partnerships, key opinion leaders (KOL) engagement and pipeline development in urologic cancers.

Bottom Line

Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Veracyte, ten years ago, you're likely feeling pretty good about your investment today.

A $1000 investment made in June 2016 would be worth $9,169.46, or a 816.95% gain, as of June 10, 2026, according to our calculations. Investors should note that this return excludes dividends but includes price increases.

In comparison, the S&P 500's gained 249.17% and the price of gold went up 221.00% over the same time frame.

Analysts are forecasting more upside for VCYT too.

Veracyte continues to scale its core testing franchise, with Decipher Prostate and Afirma driving growth through broader physician adoption and steady evidence generation. First-quarter 2026 results supported this view and led management to raise full-year revenue expectations while keeping investment plans intact. Workflow upgrades are reducing Afirma no-result rates, which supports access and helps expand operating leverage. Management is also preparing two new launches, Prosigna LDT and TrueMRD, which could widen the platform into breast and bladder recurrence settings over time. These positives are balanced by execution risk as the company scales launches, the revenue reset after the Veracyte SAS exit, and competitive and macro conditions that can influence payer behavior, costs and testing demand in the coming quarters.

Over the past four weeks, shares have rallied 24.47%, and there have been 2 higher earnings estimate revisions in the past two months for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.